Bio News
The National Growth Fund’s Fund Management Committee approved a KRW 20 billion low-interest loan for Kyongbo Pharmaceutical. Kyongbo Pharmaceutical applied for a loan from the Advanced Strategic Industries Fund to establish a dedicated antibody-drug conjugate (ADC) production facility. The company plans to complete a GMP manufacturing plant and produce clinical trial materials by the end of this year.
Biobook Team
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
